Cytomegalovirus reactivation induced acute hepatitis and gastric erosions in a patient with rheumatoid arthritis under treatment with an anti-IL-6 receptor antibody, tocilizumab

Internal Medicine

Volumn 55, Issue 14, 2016, Pages 1923-1927

  Komura, Takuya ^a,b   Ohta, Hajime ^a   Nakai, Ryotaro ^a   Seishima, Jun ^a   Yamato, Masatoshi ^a   Miyazawa, Masaki ^a   Kaji, Kiichiro ^a   Marukawa, Yohei ^a   Kagaya, Takashi ^a   Kitagawa, Kiyoki ^a   Kawashima, Atsuhiro ^a   Kaneko, Shuichi ^b   Unoura, Masashi ^a  

^a NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Acute hepatitis; Cytomegalovirus; IL 6; Tocilizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CHLORIDE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GANCICLOVIR; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6 RECEPTOR; LACTATE DEHYDROGENASE; METHOTREXATE; MONOCLONAL ANTIBODY; POTASSIUM; PREDNISOLONE; SODIUM; TOCILIZUMAB;

ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; ENDOSCOPIC ULTRASONOGRAPHY; EPIGASTRIC PAIN; FEMALE; FEVER; GASTROINTESTINAL ENDOSCOPY; HEPATOSPLENOMEGALY; HOSPITAL DISCHARGE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE DIFFERENTIAL COUNT; LIVER FUNCTION TEST; LIVER INJURY; LOSS OF APPETITE; LYMPHADENOPATHY; MIDDLE AGED; RHEUMATOID ARTHRITIS; STOMACH ANTRUM; STOMACH EROSION; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; VIREMIA; VIRUS REACTIVATION; ARTHRITIS, RHEUMATOID; CYTOMEGALOVIRUS INFECTIONS; HEPATITIS; STOMACH ULCER; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEPATITIS; HUMANS; METHOTREXATE; MIDDLE AGED; STOMACH ULCER;

EID: 84978371339     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.55.5981     Document Type: Article

References (24)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 376: 1094-1108, 2010.
2. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin-6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19: 22-25, 1992.
3. Kishimoto T. The biology of interleukin-6. Blood 74: 1-10, 1989.
4. Liuzzi JP, Lichten LA, Rivera S, et al. Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc Natl Acad Sci USA 102: 6843-6848, 2005.
5. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2: 619-626, 2006.
6. Oldfield V, Dhillon S, Plosker GL. Tocilizumab. Drugs 69: 609-632, 2009.
7. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69: 976-986, 2010.
8. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for the treatment of rheumatoid arthritis. Lancet 370: 1861-1874, 2007.
9. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev (7): CD008331, 2010.
10. Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s disease. Intern Med 46: 771-774, 2007.
11. Nagashima T, Minota S. Long-term tocilizumab therapy in patients with rheumatoid arthritis and chronic hepatitis B. Rheumatology 47: 1838-1840, 2008.
12. Feist E, Burmester GR. Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA? Nat Clin Pract Rheumatol 5: 128-129, 2009.
13. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20: 202-213, 2010.
14. Griffi T. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis 12: 790-798, 2012.
15. Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) 51: 852-857, 2012.
16. Saunders BM, Frank AA, Orme IM, Cooper AM. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun 68: 3322-3326, 2000.
17. + T cells. Blood 100: 3690-3697, 2002.
18. Murphy EA, Davis JM, Brown AS, Carmichael MD, Ghaffar A, Mayer EP. Effect of IL-6 deficiency on susceptibility to HSV-1 respiratory infection and intrinsic macrophage antiviral resistance. J Interferon Cytokine Res 28: 589-595, 2008.
19. Ogawa J, Harigai M, Akashi T, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanized anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 65: 1667-1669, 2006.
20. Kubandova Z, Mathieu S, Pourtier C, Soubrier M. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody. Joint Bone Spine 77: 623-624, 2010.
21. Roux C, Breuil V, Albert C, et al. Ophthalmic herpes zoster infection in patients with rheumatoid arthritis who were treated with tocilizumab. J Rheumatol 38: 399, 2011.
22. van Duin D, Miranda C, Husni E. Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy. Emerg Infect Dis 17: 754-756, 2011.
23. Kawada J, Iwata N, Kitagawa Y, Kimura H, Ito Y. Prospective monitoring of Epstein-Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab. Mod Rheumatol 22: 565-570, 2012.
24. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2): CD008794, 2011.